Novel Catalysts for Asymmetric Allylic Alkylation

描述(由申请人提供)：由FDA法规和 不断增长的市场，对生产手性物质的技术有很高的需求 医药中间体。钯催化的对映体选择性C-C、C-N和C-O 烯丙基上的成键取代(烯丙基取代或 烯丙化)是当前研究的一个重要领域。许多是对映体 纯净的治疗化合物和天然产物可以通过以下方法合成 这种方法论。 手性配体的设计、合成和筛选，起着举足轻重的作用。 在不对称催化发展中的作用。在第一阶段，我们建议 开发一类新的手性配体，将在钯中进行评估 基于标准模型催化不对称烯丙基取代(烯丙基化) 反应。在第二阶段，我们将对配体和反应进行优化 条件。此外，我们将把催化剂的使用范围扩大到广泛的 一系列底物，包括重要的药物中间体。在第三阶段，我们 将探索其在医药和相关化学品中的应用 工业和商业化的催化剂以及技术 工业和学术用途。 建议的商业应用： 人们对对映体纯药物的需求越来越大。Medicem建议开发新型手性卡宾过渡金属催化剂，用于不对称烯丙基烷基化，以形成立体选择性的碳-碳、碳-氮和碳-氧键。建议的催化剂将有助于合成药物和中间体，使其更加高效和对环境更加友好。

DESCRIPTION (provided by applicant): Driven by the FDA regulations and the growing market, there is a demanding need for technology to produce chiral pharmaceutical intermediates. Pd-catalyzed enantioselective C-C, C-N and C-O bond forming substitutions at allylic positions (allylic substitution or allylation) are an important area of current research. Many enantiomerically pure therapeutic compounds and natural products can be synthesized by employing this methodology. The design, synthesis and screening of chiral ligands, have played a pivotal role in the development of asymmetric catalysis. In Phase I, we propose to develop a new class of chiral ligands, which will be evaluated in palladium catalyze asymmetric allylic substitution (allylation) based on a standard model reaction. In Phase II, we are going to optimize the ligands and the reaction conditions. In addition, we will extend the use of the catalysts to a wide range of substrates including important drug intermediates. In Phase III, we will explore the applications in pharmaceutical and the related chemical industries and commercialize the catalysts as well as the technology for industrial and academic use. PROPOSED COMMERCIAL APPLICATIONS: There is an increasing need for enantiomerically pure pharmaceutical drugs. MediChem proposes to develop novel chiral carbene-transition metal catalysts for asymmetric allylic alkylation to form stereoselective carbon-carbon, carbon-nitrogen and carbon-oxygen bonds. The proposed catalysts will help synthesize pharmaceutical drugs and intermediates to be more efficient and more friendly to our environment.